* miRview Meso Test

    Every day, advances are being made in the diagnosis and treatment of mesothelioma in the hopes that someday doctors may be able to make early definitive diagnoses that allow treatment of the disease to be more successful. Historically, mesothelioma has been difficult to diagnose and equally as difficult to treat, generally because it has such a long latency period, often up to 50 years. The latency of the disease means a diagnosis is not always apparent and, by the time it is made, the disease has progressed to its later stages.

    However, thanks to the ingenuity of researchers, more tests are evolving that aid in earlier and more definitive diagnosis of this aggressive form of cancer. Such tests include the miRview Meso test, developed by Philadelphia-based Rosetta Genomics. Rosetta, established in 2000, is well known for its minimally-invasive diagnostic tests and doctors view the miRview Meso test as a big step in the right direction towards the proper diagnosis of malignant mesothelioma.

    If you would like to learn more about all stages of the diagnostic process for mesothelioma, please fill out this form to receive a comprehensive packet in the mail.

How Does it Work?

    miRview Meso is a microRNA-based molecular diagnostic tool that helps to differentiatemalignant pleural mesothelioma from peripheral adenocarcinomas of the lung or metastatic carcinomas involving the lung pleura. More simply put, this test can assist doctors in determining whether a patient has mesothelioma or some other form of lung cancer. Currently, this is the only “single” test available to definitively diagnose malignant pleural mesothelioma.

    The test uses highly-sensitive technology to measure the microRNA in a sample of tissue taken from a tumor. Specifically, it measures the expression level of three microRNA biomarkers. The test can be done in a doctor’s office or hospital setting. The sample is then sent to a lab for processing, and by use of cutting-edge technology, lab technicians are able to determine whether or not the patient has mesothelioma. Reports are generally received by the ordering doctor in about 10 days.

Benefits of the Test

    The miRview Meso test is extremely accurate. As a matter of fact, the sensitivity and specificity of this test have been shown to be about 95 percent and 96 percent. No other test is known to be this accurate in the diagnosis of mesothelioma. This is especially important because different sub-types of lung cancer can be very difficult to diagnose, even under a microscope.

    Furthermore, diagnosing mesotheliom is often a laborious process involving numerous tests such as chest X-rays, CT scans, MRIs, biopsies and more. Because the miRview test is a single one-step diagnostic procedure, results are available quickly and treatment can commence immediately, providing the patient with a better chance of survival and more treatment options.

Obtaining the Test

    Rosetta Genomic’s miRview Meso test is widely available. Most oncologists who specialize in the treatment of mesothelioma and/or other lung and thoracic cancers will probably be familiar with this diagnostic procedure. For those who are not, further information is available from Rosetta Genomics and doctors can order collection kits, sample preparation instructions, and shipping instructions from the company by phone or online.

Source : http://www.asbestos.com